Pamplona-based CDMO 3P Biopharmaceuticals (3P) has announced Keensight Capital as its new major investor after previous major investor Infarco is refocussing on international expansion. By providing 3P with leap in terms of capacity, equipment, technology, and talent, Keensight is expected to consolidate 3P’s position as one of few mid-sized CDMOs on the international market that offers commercial manufacturing capabilities.
"We are extremely enthusiastic to work with Keensight Capita at such a crucial moment for our industry," said Dámaso Molero, CEO of 3P Biopharmaceuticals. "With their global footprint and their expertise inthe biologics field, I am highly confident that Keensight team will help us reach significant milestones in the coming years.
3P experienced a 23% annual revenue growth over the past 4 years, 10% above the rate the biological CDMO market is to grow from 2018-2022. The fully integrated specialist in process development and GMP-compliant manufacturing  biologics and cell therapy products is further being funded by Sodena, the financial business development instrument of the Government of Navarra.

Merck and the Broad Institute have signed an agreement on the granting of non-exclusive intellectual property licenses to CRISPR-based genome editing.

Danish cancer antibody powerhouse Genmab plans to raise US$505m in its US IPO. The money will go towards its antibody therapeutics pipeline.

Belgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos’ pipeline and drug discovery platform.

French microalgae specialist Microphyt has raised €28.5m to develop its microalgae portfolio for nutrition and cosmetics.